Advances in CRT Device Diagnostics

  • Jeffrey Wing-Hong Fung
  • Cheuk-Man Yu


Heart Failure Heart Rate Variability Right Ventricular Chronic Heart Failure Cardiac Resynchronization Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abraham WT, Fisher WG, Smith AL, et al. MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–1853.PubMedCrossRefGoogle Scholar
  2. 2.
    Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.PubMedCrossRefGoogle Scholar
  3. 3.
    Young JB, Abraham WT, Smith AL, et al. Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. JAMA 2003;289:2685–2694.PubMedCrossRefGoogle Scholar
  4. 4.
    Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–1549.PubMedCrossRefGoogle Scholar
  5. 5.
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154–235.PubMedCrossRefGoogle Scholar
  6. 6.
    Lombardi F. Clinical implications of present physiological understanding of HRV components. Card Electrophyiol Rev 2002;6:245–249.CrossRefGoogle Scholar
  7. 7.
    Billman GE, Dujardin JP. Dynamic changes in cardiac vagal tone as measured by time-series analysis. Am J Physiol 1990;258:H896.PubMedGoogle Scholar
  8. 8.
    Pagani M, Mallini A. Interpreting oscillations of muscle sympathetic nerve activity and heart rate variability. J Hypertens 2000;18:1709–1719.PubMedCrossRefGoogle Scholar
  9. 9.
    Molgaard H, Sorensen KE, Bjerregaard P. Circadian variation and influence of risk factors on heart rate variability in healthy subjects. Am J Cardiol 1991;68:777.PubMedCrossRefGoogle Scholar
  10. 10.
    Malik M, Camm AJ, Janse MJ, et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol 2000;35:1263–1275.PubMedCrossRefGoogle Scholar
  11. 11.
    Adamson PB, Vanoli E. Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure: Characteristics of a novel heart failure model in dogs with post myocardial infarction left ventricular dysfunction. J Am Coll Cardiol 2001;37:1741–1748.PubMedCrossRefGoogle Scholar
  12. 12.
    La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials. Circulation 2001;103:2072–2077.PubMedGoogle Scholar
  13. 13.
    Fantoni C, Raffa S, Regoli F, et al. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol 2005;46:1875–1882.PubMedCrossRefGoogle Scholar
  14. 14.
    Adamson PB, Smith AL, Abraham WT, et al. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 2004;110:2389–2394.PubMedCrossRefGoogle Scholar
  15. 15.
    Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK heart). Circulation 1998;98: 1510–1516.PubMedGoogle Scholar
  16. 16.
    La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003;107:565–570.PubMedCrossRefGoogle Scholar
  17. 17.
    Mortara A, La Rovere MT, Pinna GD, et al. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroreflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000;36:1612–1618.PubMedCrossRefGoogle Scholar
  18. 18.
    Adamson PB, Kleckner KJ, VanHout WL, et al. Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circulation 2003;108:266–269.PubMedCrossRefGoogle Scholar
  19. 19.
    Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361–371.PubMedCrossRefGoogle Scholar
  20. 20.
    Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. Circulation 1993;87(Suppl VI); VI-102–VI-110.Google Scholar
  21. 21.
    Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87 (Suppl VI):VI-5–VI-16.Google Scholar
  22. 22.
    Francis GS, Rector TS. Maximal exercise tolerance as a therapeutic end point in heart failure—are we relying on the right measure? Am J Cardiol 1994;73: 304–306.PubMedCrossRefGoogle Scholar
  23. 23.
    Walsh JT, Charlesworth A, Andrews R, Hawkins M, Cowley AJ. Relation of daily activity levels in patients with chronic heart failure to long-term prognosis. Am J Cardiol 1997;79:1364–1369.PubMedCrossRefGoogle Scholar
  24. 24.
    Braunschweig F, Mortensen PT, Gras D, et al. Monitoring of physical activity and heart rate variability in patients with chronic heart failure using cardiac resynchronization devices. Am J Cardiol 2005;95:1104–1107.PubMedCrossRefGoogle Scholar
  25. 25.
    Goldberg LR, Piette JD, Walsh MN, et al. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: The weight monitoring in heart failure (WHARF) trial. Am Heart J 2003;46:705–712.CrossRefGoogle Scholar
  26. 26.
    Louis AA, Turner T, Gretton M, et al. A systematic review of telemonitoring for the management of heart failure. Eur J Heart Fail 2003;5:583–590.PubMedCrossRefGoogle Scholar
  27. 27.
    Friedman MM. Older adults’ symptoms and their duration before hospitalization for heart failure. Heart Lung 1997;26:169–176.PubMedCrossRefGoogle Scholar
  28. 28.
    Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884–888.PubMedCrossRefGoogle Scholar
  29. 29.
    Luepker RV, Michael JR, Warbasse JR. Transthoracic electrical impedance; quantitative evaluation of a non-invasive measure of thoracic fluid volume. Am Heart J 1973;85:83–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Baker LE, Denniston JC. Noninvasive measurement of intrathoracic fluids. Chest 1974;65(Suppl):37S.CrossRefGoogle Scholar
  31. 31.
    Fein A, Grossman RF, Jones JG, et al. Evaluation of transthoracic electrical impedance in the diagnosis of pulmonary edema. Circulation 1979;60:1156–1160.PubMedGoogle Scholar
  32. 32.
    Saunders CE. The use of transthoracic electrical bioimpedance in assessing thoracic fluid status in emergency department patients. Am J Emerg Med 1988;6:337–340.PubMedCrossRefGoogle Scholar
  33. 33.
    Ramos MU, LaBree JW, Remole W, Kubicek WG. Transthoracic electric impedance. A clinical guide of pulmonary fluid accumulation in congestive heart failure. Minn Med 1975;58:671–676.PubMedGoogle Scholar
  34. 34.
    Yamamoto T, Yamamoto Y, Ozawa T. Characteristics of skin admittance for dry electrodes and the measurement of skin moisturisation. Med Biol Eng Comput 1986;24:71–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Wang L, Lahtinen S, Lentz L, et al. Feasibility of using an implantable system to measure thoracic congestion in an ambulatory chronic heart failure canine model. Pacing Clin Electrophysiol 2005;28:404–411.PubMedCrossRefGoogle Scholar
  36. 36.
    Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: Correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005;112:841–848.PubMedCrossRefGoogle Scholar
  37. 37.
    Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: Clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003;41:565–571.PubMedCrossRefGoogle Scholar
  38. 38.
    Komajda M, Follath F, Swedberg K, et al; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24: 464–474.PubMedCrossRefGoogle Scholar
  39. 39.
    Fung JW, Chan JY, Leo CC, et al. Suboptimal medical therapy in patients with systolic heart failure is associated with less improvement by cardiac resynchronization therapy. Int J Cardiol 2007;115:214–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation 2004;110:3518–3526.PubMedCrossRefGoogle Scholar
  41. 41.
    Fung JW, Yu CM, Chan JY, et al. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol 2005;96:728–731.PubMedCrossRefGoogle Scholar
  42. 42.
    Cleland JGF, Louis AA, Rigby AS, et al., on behalf of the TEN-HMS Investigators. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol 2005;45:1654–1664.PubMedCrossRefGoogle Scholar
  43. 43.
    Kjellstrom B, Igel D, Abraham J, Bennett T, Bourge R. Trans-telephonic monitoring of continuous haemodynamic measurements in heart failure patients. J Telemed Telecare 2005;11:240–244.PubMedCrossRefGoogle Scholar
  44. 44.
    Adamson PB. Continuous heart rate variability from a cardiac resynchronization device-prognostic value and clinical application. In: Yu CM, Hayes DL, Auricchio A, eds. Cardiac Resynchronization Therapy. Blackwell Futura, Massachusetts, USA; 2006;303–309.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jeffrey Wing-Hong Fung
  • Cheuk-Man Yu

There are no affiliations available

Personalised recommendations